The News Review:

- Clinsys Partners with Medidata Solutions through ASPire to win…
- New Method Effective In Detecting Dangerous Coronary Plaque
- RTG Study: Adding Cetuximab to Chemotherapy and Radiotherapy Leads…

Clinsys Partners with Medidata Solutions through ASPire to win…
The Cheers – May 31, 2008
Clinsys provides pharmaceutical biotechnology and medical device companies with a full range of clinical research services in support of Phase I-IV drug and device development. With extensive experience and expertise in specialized therapeutic areas including oncology central nervous system dermatology respiratory and cardiovascular Clinsys looked for an electronic data capture (EDC) partner that offered innovative Web-based technology with secure reliable and scalable hosting in order to reduce both implementation time and total cost of ownership. Clinsys selected Medidata as its EDC provider due to sponsor demand for Rave’s Web-based site-friendly features that help to increase EDC usage. “For a CR having more data collection choices enables us to deliver customized projects that meet our customers’ objectives and we know that clients prefer custom solutions rather than a ‘one type fits all’ approach” said Ferrell Drewry Chief Information fficer and Vice President Biometrics at Clinsys. “ur participation in the ASPire to Win program furthers our ability to deliver high-quality robust and cost-effective clinical trial solutions and is another example of our dedication to aligning our company with the best technology partners.

New Method Effective In Detecting Dangerous Coronary Plaque
Science Daily – Science Daily (press release) – May 31, 2008
)Coauthors of the AJR report include Vassilios Raptopoulos Adeel Sabir Norihiko Yoshimura and Shezhang Lin of BIDMC’s Department of Radiology; Francine Welty and Pedro Martinez-Clark of BIDMC’s Department of Cardiology; and Jacqueline Buros of the PERFUSE Core Laboratory and Data Coordinating Center Harvard Medical School. Funded by the National Heart Lung and Blood Institute (NHLB) the trial will be conducted at Beth Israel Deaconess Medical Center Joslin Diabetes Center and Tufts New England Medical Center. Leading the TINSAL-CVD study are Allison Goldfine MD Director of Clinical Research at Joslin Diabetes Center; Steven Shoelson MD PhD of Joslin Diabetes Center; Ernest Schaefer MD of The Jean Mayer USDA Human Nutrition Center on Aging at Tufts University; BIDMC cardiologist Francine Welty MD PhD and BIDMC Director of Radiology Research Melvin Clouse MD. Adapted from materials provided by.

RTG Study: Adding Cetuximab to Chemotherapy and Radiotherapy Leads…
Genetic Engineering News – Genetic Engineering News (press release) – May 31, 2008
Investigators for RTG an NCI-funded national cooperative clinical trials group and clinical research enterprise component of the American College of Radiology (ACR) presented their results today at the American Society of Clinical ncology?s 44th Annual Meeting in Chicago. Cetuximab has been shown to enhance the activity of radiation therapy.